Dermatitis News

DS Biopharma announced positive results from a phase 2a clinical trial of DS107 as an oral treatment in patients with moderate-to-severe atopic dermatitis.

Immune Pharmaceuticals announced that based on efficacy data, it will partner with BioNanoSim Ltd to develop and license a novel topical nano-capsule formulation of cyclosporine for treating chronic inflammatory skin disorders such as moderate atopic dermatitis and psoriasis.

Oculus Innovative Sciences announced in a press release that the FDA has granted 510(k) clearance for it Microcyn-based SebDermGel to treat seborrheic dermatitis.

Recent research in JAMA Pediatrics revealed an association between anemia and atopic diseases, such as asthma, eczema, hay fever and food allergies, in children and adolescents.

Patients who received melatonin had improved atopic dermatitis management and time to sleep-onset, according to recent research published in JAMA Pediatrics.

Study results finding that patients with severe nail dystrophy related to alopecia universalis who were treated with Xeljanz experienced normal nail growth was the most read-article of the past week on Healio.com/Dermatology.

The American Academy of Dermatology has released a free mobile app, which offers tools and resources for patients with chronic urticaria management.

LEO Pharma A/S announced in a press release that it has entered into an asset purchase agreement to acquire Astellas’ global dermatology portfolio for $727 million.

SAN ANTONIO — Breastfeeding did not appear to have any effect on immunoglobulin E sensitization to environmental allergens among children with symptoms of rhinitis, according to study results presented at the 2015 American College of Allergy, Asthma and Immunology Annual Scientific Meeting.

Study results reporting that men treated with Kybella in phase 3 trials had a reduction in submental fat and were satisfied with treatment was the most read-article of the past week on Healio.com/Dermatology.